AstraZeneca’s growth was driven by its portfolio of products in the oncology, biopharmaceuticals and rare disease segments ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Recent results from the NIAGARA trial, which evaluated using the immune checkpoint inhibitor durvalumab in combination with ...

Adjuvant durvalumab did not improve disease-free survival in patients with early-stage non-small cell lung cancer in the phase 3 BR.31 trial.

Perioperative durvalumab has “the potential to transform the standard of care” for patients with muscle-invasive bladder ...

NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.

Therapeutics and collaborators at The University of Texas MD Anderson Cancer Center presented late-breaking results from a Phase ...